GAD1 and type 1 diabetes mellitus: Our study confirms an accelerated onset of T1D, increased GAD-reactive T cell frequency in spleen, precipitated destruction of β cells, triggering of high glucose levels, and pancreatic islet reduction in susceptible NOD/ShiLtJ mice treated with murine anti–PD-1 mAb.